Xarelto Clinical Trials
Here are the 6 most popular medical studies for xarelto
Anticoagulant
Anticoagulation for Atrial Fibrillation Post-Ablation
Recruiting3 awardsPhase 4
Calgary, Alberta
This trial is comparing medical approaches for stroke prevention in people who have atrial fibrillation (AF) and have undergone a successful procedure called ablation to eliminate or substantially reduce the arrhythmia.
Monoclonal Antibodies
Abelacimab vs. Rivaroxaban for Atrial Fibrillation
Recruiting1 awardPhase 2
Huntsville, Alabama
This trial is looking at whether a new drug, abelacimab, is better than the current standard of care, rivaroxaban, at reducing bleeding in patients with a heart condition called atrial fibrillation.
Popular filter options for xarelto trials
Phase 3 Clinical Trials
View 30 phase 3 medical studies.
Anticoagulant
Rivaroxaban + Ticagrelor for Atrial Fibrillation After Stent Placement
Recruiting2 awardsPhase 3
Ottawa, Ontario
This trial is studying the combination of two potent drugs, ticagrelor and rivaroxaban, in AF patients receiving a stent placement, in order to gain insight into the management of these high-risk patients.
Anticoagulant
Rivaroxaban for Portal Vein Thrombosis
Recruiting4 awardsPhase 3
Hamilton
Anticoagulant therapy is generally recommended for all patients presenting with acute symptomatic splanchnic vein thrombosis, starting with either low-molecular weight heparin (LMWH) or unfractionated heparin and continuing with the vitamin K antagonists in most patients. Rivaroxaban is approved for the treatment of deep vein thrombosis and pulmonary embolism, but no studies have assessed the safety of rivaroxaban in the setting of splanchnic vein thrombosis. The investigators aim to collect prospective information on the safety of rivaroxaban in a pilot cohort of 100 patients with acute splanchnic vein thrombosis without liver cirrhosis.
Clinical Trials With No Placebo
View 30 medical studies that do not have a placebo group.
Anticoagulant
Anticoagulants vs Antiplatelets for Blood Clot Prevention After Heart Procedure
Recruiting3 awardsPhase 4
Quebec
This trial compares two ways to prevent blood clots around a device used to treat heart problems. One is a short course of a blood thinner called a DOAC. The other is a daily antiplatelet pill.
Anticoagulant
Rivaroxaban + Ticagrelor for Atrial Fibrillation After Stent Placement
Recruiting2 awardsPhase 3
Ottawa, Ontario
This trial is studying the combination of two potent drugs, ticagrelor and rivaroxaban, in AF patients receiving a stent placement, in order to gain insight into the management of these high-risk patients.
View More Xarelto Trials
See another 15 medical studies focused on xarelto.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.